Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13657956 | 0.88 | LMNA (0.63) | L3MBTL1KCNH2CACNA1ISIGMAR1MEN1 | |
| SCHEMBL12074098 | 0.84 | L3MBTL1 (0.75) | L3MBTL1SIGMAR1MEN1KMT2ALMNA | |
| SCHEMBL17450402 | 0.84 | L3MBTL1 (0.63) | L3MBTL1SIGMAR1MEN1KMT2ALMNA | |
| SCHEMBL13847101 | 0.82 | SIGMAR1 (0.72) | SIGMAR1MEN1KMT2A | |
| SCHEMBL12139819 | 0.81 | MEN1 (0.67) | MEN1KMT2ASLC6A5LMNAALDH1A1 | |
| SCHEMBL14924027 | 0.81 | L3MBTL1 (0.55) | L3MBTL1SIGMAR1MEN1KMT2ALMNA | |
| SCHEMBL13621157 | 0.80 | SIGMAR1 (0.66) | L3MBTL1SIGMAR1MEN1KMT2ALMNA | |
| SCHEMBL4070621 | 0.78 | SIGMAR1 (0.69) | L3MBTL1SIGMAR1LMNAALDH1A1 | |
| SCHEMBL18580208 | 0.75 | L3MBTL1 (0.49) | L3MBTL1SIGMAR1MEN1KMT2ALMNA | |
| SCHEMBL7844706 | 0.74 | ALDH1A1 (0.63) | LMNAALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160229868-A1 | NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY | HANMI SCIENCE CO., LTD (KR) | 2016-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160229868-A1 | NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY | LCK, LTK, FYN | L3MBTL1 2596/4885KCNH2 4108/4885CACNA1I 4835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.